BPI fold containing family B member 2Genealiases: BPIL1 · C20orf184 · LPLUNC2 · RYSR · dJ726C3.2
Q-omics provides the consensus-scored BPIFB2 profile across patient tissues and cancer cell-line models. BPIFB2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, BPIFB2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, BPIFB2 protein abundance shows 17,796 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, and HNSC as cancer lineages where BPIFB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFB2 survival associations across molecular data types. BPIFB2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFB2 RNA expression–survival associations across cancer types. High BPIFB2 expression shows unfavorable associations in KICH, BLCA and KIRC, but favorable associations in UCEC, LUSC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for BPIFB2 RNA expression.
This table summarizes BPIFB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BPIFB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFB2 shows lower tumor expression in HNSC and BRCA and higher tumor expression in LIHC, LUAD, UCEC and PRAD. The HNSC box plot shows higher BPIFB2 RNA expression in normal versus tumor tissue (log2 FC = −2.918, t-test p < 0.001).
This table shows molecular features associated with BPIFB2 in patient tissues and cancer cell lines. In patient samples, BPIFB2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
